常山药业
(300255)
| 流通市值：432.87亿 | | | 总市值：433.70亿 |
| 流通股本：9.17亿 | | | 总股本：9.19亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 491,607,943.46 | 258,703,492.68 | 1,030,810,532.63 | 784,021,902.08 |
| 营业收入 | 491,607,943.46 | 258,703,492.68 | 1,030,810,532.63 | 784,021,902.08 |
| 二、营业总成本 | 546,995,010.72 | 262,354,455.18 | 1,246,949,473.64 | 874,012,625.11 |
| 营业成本 | 420,137,928.8 | 198,942,323.28 | 864,815,798.75 | 642,451,312.26 |
| 税金及附加 | 6,828,327.74 | 2,833,724.78 | 13,368,674.82 | 7,902,150.2 |
| 销售费用 | 10,438,225.9 | 5,169,219.27 | 90,021,285.57 | 42,991,269.39 |
| 管理费用 | 51,986,883.53 | 24,281,428.63 | 130,317,232.64 | 90,016,432.34 |
| 研发费用 | 15,845,961.33 | 10,199,286.3 | 47,189,438.45 | 23,438,244.55 |
| 财务费用 | 41,757,683.42 | 20,928,472.92 | 101,237,043.41 | 67,213,216.37 |
| 其中:利息费用 | 48,924,439.19 | 21,327,477.37 | 102,830,310.85 | 68,699,138.49 |
| 其中:利息收入 | 1,070,116.13 | 384,451.03 | 3,756,865.58 | 2,527,674.79 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | - | - | 33,263,558.02 | - |
| 资产处置收益 | 17,641.19 | - | -63,301.42 | -2,070.63 |
| 资产减值损失(新) | 11,840,687.94 | - | -69,834,000.43 | 1,391,537.32 |
| 信用减值损失(新) | 6,947,297.19 | 5,492,385.5 | -19,553,146.87 | 531,492.7 |
| 其他收益 | 3,026,467.02 | 1,072,925.74 | 18,283,499.2 | 30,589,042.11 |
| 四、营业利润 | -33,554,973.92 | 2,914,348.74 | -254,042,332.51 | -57,480,721.53 |
| 加:营业外收入 | 659,338.12 | 603,005.78 | 1,644,147.1 | 34,603,840.21 |
| 减:营业外支出 | 246,288.81 | 81,957.15 | 4,680,420.17 | 2,628,019.53 |
| 五、利润总额 | -33,141,924.61 | 3,435,397.37 | -257,078,605.58 | -25,504,900.85 |
| 减:所得税费用 | 3,078,672.74 | 1,808,260.75 | 6,953,235.63 | 2,301,122.67 |
| 六、净利润 | -36,220,597.35 | 1,627,136.62 | -264,031,841.21 | -27,806,023.52 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -36,220,597.35 | 1,627,136.62 | -264,031,841.21 | -27,806,023.52 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -29,088,953.45 | 3,782,609.17 | -249,477,725.95 | 7,290,091.73 |
| 少数股东损益 | -7,131,643.9 | -2,155,472.55 | -14,554,115.26 | -35,096,115.25 |
| 扣除非经常损益后的净利润 | -30,258,885.78 | 3,012,013.65 | -286,348,458.92 | -28,149,347.85 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.03 | 0 | -0.27 | 0.01 |
| (二)稀释每股收益 | -0.03 | 0 | -0.27 | 0.01 |
| 八、其他综合收益 | -276,753.15 | -74,150.97 | 79,037.21 | 2,004.77 |
| 归属于母公司股东的其他综合收益 | -276,753.15 | -74,150.97 | 79,037.21 | 2,004.77 |
| 九、综合收益总额 | -36,497,350.5 | 1,552,985.65 | -263,952,804 | -27,804,018.75 |
| 归属于母公司股东的综合收益总额 | -29,365,706.6 | 3,708,458.2 | -249,398,688.74 | 7,292,096.5 |
| 归属于少数股东的综合收益总额 | -7,131,643.9 | -2,155,472.55 | -14,554,115.26 | -35,096,115.25 |
| 公告日期 | 2025-08-23 | 2025-04-29 | 2025-04-29 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |